New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareChonluten vs HGH Fragment 176-191

Chonluten vs HGH Fragment 176-191

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Chonluten
Fat Loss & Metabolic
HGH Fragment 176-191
Summary
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
Half-Life
Short (minutes for the peptide); sustained gene-regulatory effects
~30 minutes
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
250–500 mcg
Frequency
Daily for 10–30 days
1–3 times daily
Key Benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
  • Selective fat burning without anabolic side effects
  • Reduces visceral and subcutaneous fat
  • No insulin resistance or blood glucose disruption
  • Does not stimulate IGF-1
  • May support cartilage and bone repair (at higher doses)
  • No effect on growth or organ size
Side Effects
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
  • Injection site irritation
  • Temporary lethargy
  • Headache (rare)
  • Nausea (rare)
Stacks With